Combination Lorcaserin and Nicotine Patch for Smoking Cessation Without Weight Gain

Overview

Journal Nicotine Tob Res

Publisher Oxford University Press

Specialty Public Health

Date 2019 Oct 8

PMID 31589323

Citations 3

Authors

Jed E Rose

James M Davis

Affiliations

Soon will be listed here.

Abstract

Introduction: This study explored the efficacy of combination lorcaserin and nicotine patch for smoking cessation treatment and prevention of postsmoking cessation weight gain.

Methods: We conducted a trial in which 61 adult daily smokers were asked to quit smoking using a combination of lorcaserin and nicotine patch. During the first 2 weeks of treatment prior to the quit day, participants were randomized to receive either lorcaserin (10 mg twice daily) plus nicotine patch (21 mg) or placebo plus nicotine patch (21 mg). Following this 2-week period, participants received both medications for 12 weeks. Outcomes included 4-week continuous smoking abstinence at the end of treatment (weeks 7-10 postquit attempt), weight change, ad libitum smoking, withdrawal symptoms, and ratings of cigarette reward.

Results: Biochemically confirmed continuous smoking abstinence from 7 to 10 weeks postquit attempt was 31.1% (90% confidence interval, 21.4%-40.8%). Participants who quit smoking showed no weight gain; in fact, mean weight change was minus 0.16 kg (SD = 3.27) over the study period. There was an unexpected but strong association (p = .006) between a decrease in sensory enjoyment of smoking and successful quit outcome on this regimen. During the prequit randomization period, lorcaserin versus placebo reduced the impact of smoking to relieve craving for cigarettes as well as the sensory enjoyment of smoking (p = .005). Adherence and tolerability to lorcaserin and nicotine patch was good.

Conclusions: The combination of lorcaserin and nicotine patch was well tolerated, associated with a relatively high smoking abstinence rate, and effectively prevented weight gain associated with quitting smoking.

Implications: This report provides an important contribution to the literature because it details evidence of a medication combination-lorcaserin and nicotine-that is effective for smoking cessation and for ameliorating weight gain associated with smoking cessation. For many smokers, postcessation weight gain is a major obstacle to quitting, and this medication combination provides a suitable treatment option for these smokers.

Clinical Trial Registration: NCT02906644.

Citing Articles

Varenicline and Lorcaserin for Smoking Cessation and Weight Gain Prevention: A Randomized Clinical Trial.

Hurt R, Croghan I, Schroeder D, Choi D, Fischer K, Fokken S Mayo Clin Proc Innov Qual Outcomes. 2022; 6(5):465-474.

PMID: 36160639 PMC: 9500518. DOI: 10.1016/j.mayocpiqo.2022.01.004.

Interventions for preventing weight gain after smoking cessation.

Hartmann-Boyce J, Theodoulou A, Farley A, Hajek P, Lycett D, Jones L Cochrane Database Syst Rev. 2021; 10:CD006219.

PMID: 34611902 PMC: 8493442. DOI: 10.1002/14651858.CD006219.pub4.

Lateral Habenula 5-HT Receptor Function Is Altered by Acute and Chronic Nicotine Exposures.

Bombardi C, Delicata F, Tagliavia C, Grandis A, Pierucci M, Marino Gammazza A Int J Mol Sci. 2021; 22(9).

PMID: 33946328 PMC: 8124296. DOI: 10.3390/ijms22094775.

References

McKee S, Weinberger A, Shi J, Tetrault J, Coppola S . Developing and validating a human laboratory model to screen medications for smoking cessation. Nicotine Tob Res. 2012; 14(11):1362-71. PMC: 3482010. DOI: 10.1093/ntr/nts090. View

Cappelleri J, Bushmakin A, Baker C, Merikle E, Olufade A, Gilbert D . Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav. 2006; 32(5):912-23. DOI: 10.1016/j.addbeh.2006.06.028. View

Tuovinen E, Saarni S, Kinnunen T, Ollila H, Ruokolainen O, Patja K . Weight concerns as a predictor of smoking cessation according to nicotine dependence: A population-based study. Nordisk Alkohol Nark. 2020; 35(5):344-356. PMC: 7434149. DOI: 10.1177/1455072518800217. View

Williamson D, Madans J, Anda R, Kleinman J, Giovino G, Byers T . Smoking cessation and severity of weight gain in a national cohort. N Engl J Med. 1991; 324(11):739-45. DOI: 10.1056/NEJM199103143241106. View

Aubin H, Farley A, Lycett D, Lahmek P, Aveyard P . Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ. 2012; 345:e4439. PMC: 3393785. DOI: 10.1136/bmj.e4439. View

Farley A, Hajek P, Lycett D, Aveyard P . Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2012; 1:CD006219. DOI: 10.1002/14651858.CD006219.pub3. View

Norregaard J, Tonnesen P, Petersen L . Predictors and reasons for relapse in smoking cessation with nicotine and placebo patches. Prev Med. 1993; 22(2):261-71. DOI: 10.1006/pmed.1993.1021. View

Teneggi V, Tiffany S, Squassante L, Milleri S, Ziviani L, Bye A . Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawal. Psychopharmacology (Berl). 2002; 164(2):177-87. DOI: 10.1007/s00213-002-1176-1. View

Filozof C, Fernandez Pinilla M, Fernandez-Cruz A . Smoking cessation and weight gain. Obes Rev. 2004; 5(2):95-103. DOI: 10.1111/j.1467-789X.2004.00131.x. View

10.

Shanahan W, Rose J, Glicklich A, Stubbe S, Sanchez-Kam M . Lorcaserin for Smoking Cessation and Associated Weight Gain: A Randomized 12-Week Clinical Trial. Nicotine Tob Res. 2016; 19(8):944-951. DOI: 10.1093/ntr/ntw301. View

11.

Roche D, Bujarski S, Moallem N, Guzman I, Shapiro J, Ray L . Predictors of smoking lapse in a human laboratory paradigm. Psychopharmacology (Berl). 2014; 231(14):2889-97. DOI: 10.1007/s00213-014-3465-x. View

12.

Smith S, Weissman N, Anderson C, Sanchez M, Chuang E, Stubbe S . Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010; 363(3):245-56. DOI: 10.1056/NEJMoa0909809. View

13.

Borrelli B, Spring B, Niaura R, Hitsman B, Papandonatos G . Influences of gender and weight gain on short-term relapse to smoking in a cessation trial. J Consult Clin Psychol. 2001; 69(3):511-5. DOI: 10.1037//0022-006x.69.3.511. View

14.

Cahill K, Stevens S, Perera R, Lancaster T . Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013; (5):CD009329. PMC: 8406789. DOI: 10.1002/14651858.CD009329.pub2. View

15.

Pistelli F, Aquilini F, Carrozzi L . Weight gain after smoking cessation. Monaldi Arch Chest Dis. 2009; 71(2):81-7. DOI: 10.4081/monaldi.2009.367. View

16.

Fidler M, Sanchez M, Raether B, Weissman N, Smith S, Shanahan W . A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011; 96(10):3067-77. DOI: 10.1210/jc.2011-1256. View

17.

Levin E, Johnson J, Slade S, Wells C, Cauley M, Petro A . Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats. J Pharmacol Exp Ther. 2011; 338(3):890-6. PMC: 3164341. DOI: 10.1124/jpet.111.183525. View

18.

Gustafson A, King C, Rey J . Lorcaserin (Belviq): A Selective Serotonin 5-HT2C Agonist In the Treatment of Obesity. P T. 2013; 38(9):525-34. PMC: 3828930. View

19.

Shiffman S, Jarvik M . Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology (Berl). 1976; 50(1):35-9. DOI: 10.1007/BF00634151. View

20.

OHara P, Connett J, Lee W, Nides M, Murray R, Wise R . Early and late weight gain following smoking cessation in the Lung Health Study. Am J Epidemiol. 1998; 148(9):821-30. DOI: 10.1093/oxfordjournals.aje.a009706. View